Miruvor
Sign up
The short answer

What studies of Casirivimab-imdevimab (REGEN-COV) found

1paper on Casirivimab-imdevimab (REGEN-COV)
3 (few people)people in 1 study testing Casirivimab-imdevimab (REGEN-COV) alone
0randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty): 9 findings, all C.

9 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Casirivimab-imdevimab (REGEN-COV) might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects and all 1 paper.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Casirivimab-imdevimab (REGEN-COV) · Long COVID is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Autonomic symptoms1 study · 3 (few people) people received Casirivimab-imdevimab (REGEN-COV) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (3 in all); not all results were tested against chance.

Studies with no comparison group3 in the study · minimally, for two years (few people)

Autonomic symptoms improved.

The evidence is very uncertain about the effect of casirivimab-imdevimab (REGEN-COV) on autonomic symptoms in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (3 in all)
  • Not all results were tested against chance
See the 1 study
  1. Remission of severe forms of long COVID following monoclonal antibody (MCA) infusions: A report of signal index cases and call for targeted research. (2024)

    People in the study
    3 in the study
    Dose
    —
    Outcome
    Heart Racing/ Palpitations
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Breathlessness1 study · 3 (few people) people received Casirivimab-imdevimab (REGEN-COV) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (3 in all); not all results were tested against chance.

Studies with no comparison group3 in the study · minimally, for two years (few people)

Breathlessness improved.

The evidence is very uncertain about the effect of casirivimab-imdevimab (REGEN-COV) on breathlessness in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (3 in all)
  • Not all results were tested against chance
See the 1 study
  1. Remission of severe forms of long COVID following monoclonal antibody (MCA) infusions: A report of signal index cases and call for targeted research. (2024)

    People in the study
    3 in the study
    Dose
    —
    Outcome
    Shortness of Breath
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Cognition (brain fog)1 study · 3 (few people) people received Casirivimab-imdevimab (REGEN-COV) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (3 in all); not all results were tested against chance.

Studies with no comparison group3 in the study · minimally, for two years (few people)

Cognition (brain fog) improved.

The evidence is very uncertain about the effect of casirivimab-imdevimab (REGEN-COV) on cognition (brain fog) in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (3 in all)
  • Not all results were tested against chance
See the 1 study
  1. Remission of severe forms of long COVID following monoclonal antibody (MCA) infusions: A report of signal index cases and call for targeted research. (2024)

    People in the study
    3 in the study
    Dose
    —
    Outcome
    Brain Fog/Difficulty Concentrating
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Fatigue1 study · 3 (few people) people received Casirivimab-imdevimab (REGEN-COV) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (3 in all); not all results were tested against chance.

Studies with no comparison group3 in the study · minimally, for two years (few people)

Fatigue improved.

The evidence is very uncertain about the effect of casirivimab-imdevimab (REGEN-COV) on fatigue in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (3 in all)
  • Not all results were tested against chance
See the 1 study
  1. Remission of severe forms of long COVID following monoclonal antibody (MCA) infusions: A report of signal index cases and call for targeted research. (2024)

    People in the study
    3 in the study
    Dose
    —
    Outcome
    Physical Fatigue (Lack of energy)
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Low mood or anxiety1 study · 3 (few people) people received Casirivimab-imdevimab (REGEN-COV) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (3 in all); not all results were tested against chance.

Studies with no comparison group3 in the study · minimally, for two years (few people)

Low mood or anxiety improved.

The evidence is very uncertain about the effect of casirivimab-imdevimab (REGEN-COV) on low mood or anxiety in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (3 in all)
  • Not all results were tested against chance
See the 1 study
  1. Remission of severe forms of long COVID following monoclonal antibody (MCA) infusions: A report of signal index cases and call for targeted research. (2024)

    People in the study
    3 in the study
    Dose
    —
    Outcome
    Emotional Lability
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Pain1 study · 3 (few people) people received Casirivimab-imdevimab (REGEN-COV) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (3 in all); not all results were tested against chance.

Studies with no comparison group3 in the study · minimally, for two years (few people)

Pain improved.

The evidence is very uncertain about the effect of casirivimab-imdevimab (REGEN-COV) on pain in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (3 in all)
  • Not all results were tested against chance
See the 1 study
  1. Remission of severe forms of long COVID following monoclonal antibody (MCA) infusions: A report of signal index cases and call for targeted research. (2024)

    People in the study
    3 in the study
    Dose
    —
    Outcome
    Joint Pain
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Sleep1 study · 3 (few people) people received Casirivimab-imdevimab (REGEN-COV) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (3 in all); not all results were tested against chance.

Studies with no comparison group3 in the study · minimally, for two years (few people)

Sleep improved.

The evidence is very uncertain about the effect of casirivimab-imdevimab (REGEN-COV) on sleep in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (3 in all)
  • Not all results were tested against chance
See the 1 study
  1. Remission of severe forms of long COVID following monoclonal antibody (MCA) infusions: A report of signal index cases and call for targeted research. (2024)

    People in the study
    3 in the study
    Dose
    —
    Outcome
    Difficulty with Sleep/Unrestful Sleep
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Daily functioning1 study · 3 (few people) people received Casirivimab-imdevimab (REGEN-COV) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (3 in all); not all results were tested against chance.

Studies with no comparison group3 in the study · minimally, for two years (few people)

Daily functioning improved.

The evidence is very uncertain about the effect of casirivimab-imdevimab (REGEN-COV) on daily functioning in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (3 in all)
  • Not all results were tested against chance
See the 1 study
  1. Remission of severe forms of long COVID following monoclonal antibody (MCA) infusions: A report of signal index cases and call for targeted research. (2024)

    People in the study
    3 in the study
    Dose
    —
    Outcome
    Exercise Intolerance (Distance walked/ Ability to climb stairs)
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Overall symptoms1 study · 3 (few people) people received Casirivimab-imdevimab (REGEN-COV) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (3 in all); not all results were tested against chance.

Studies with no comparison group3 in the study · minimally, for two years (few people)

Overall symptoms improved.

The evidence is very uncertain about the effect of casirivimab-imdevimab (REGEN-COV) on overall symptoms in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (3 in all)
  • Not all results were tested against chance
See the 1 study
  1. Remission of severe forms of long COVID following monoclonal antibody (MCA) infusions: A report of signal index cases and call for targeted research. (2024)

    People in the study
    3 in the study
    Dose
    —
    Outcome
    Total Score
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Side effects

Side effects studies reported1 kind
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Worse symptoms or a flare1 study

All papers

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime